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Abstract
Aims: The dual oxidase 2 (DUOX2) protein belongs to the NADPH oxidase (NOX) family. As H2O2 generator,
it plays a key role in both thyroid hormone biosynthesis and innate immunity. DUOX2 forms with its matu-
ration factor, DUOX activator 2 (DUOXA2), a stable complex at the cell surface that is crucial for the H2O2-
generating activity, but the nature of their interaction is unknown. The contribution of some cysteine residues
located in the N-terminal ectodomain of DUOX2 in a surface protein–protein interaction is suggested. We have
investigated the involvement of different cysteine residues in the formation of covalent bonds that could be of
critical importance for the function of the complex. Results: We report the identification and the character-
ization of an intramolecular disulfide bond between cys-124 of the N-terminal ectodomain and cys-1162 of an
extracellular loop of DUOX2, which has important functional implications in both export and activity of
DUOX2. This intramolecular bridge provides structural support for the formation of interdisulfide bridges
between the N-terminal domain of DUOX2 and the two extracellular loops of its partner, DUOXA2.
Innovation: Both stability and function of the maturation factor, DUOXA2, are dependent on the oxidative
folding of DUOX2, indicating that DUOX2 displays a chaperone-like function with respect to its partner.
Conclusions: The oxidative folding of DUOX2 that takes place in the endoplasmic reticulum (ER) appears to
be a key event in the trafficking of the DUOX2/DUOXA2 complex as it promotes an appropriate conformation
of the N-terminal region, which is propitious to subsequent covalent interactions with the maturation factor,
DUOXA2. Antioxid. Redox Signal. 23, 724–733.
Introduction
The dual oxidase 2 (DUOX2) protein belongs to theNADPH oxidase (NOX/DUOX) family. DUOX2 and
its counterpart, DUOX1, were initially identified as H2O2
sources involved in thyroperoxidase-mediated iodide orga-
nification during thyroid hormone biosynthesis (4, 5). The
discovery of congenital hypothyroidism resulting from in-
Innovation
Both stability and function of the maturation factor,
dual oxidase activator 2 (DUOXA2), are totally dependent
on the oxidative folding of dual oxidase 2 (DUOX2), in-
dicating that DUOX2 displays a chaperone-like function
with respect to its partner.
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activating mutations of the DUOX2 gene highlighted that
DUOX2 is actually the main H2O2 provider of the thyr-
operoxidase (16–18). Far from being ubiquitous, DUOX2 is
not restricted to the thyroid. It is also well expressed in the
respiratory tract epithelium and in the gastrointestinal mu-
cosa where it plays a key role in antimicrobial defense (8).
Overexpression of the DUOX2 gene has been associated with
an increasing number of inflammation diseases, such as
Crohn’s disease (2), irritable bowel syndrome (1), and heli-
cobacter-associated gastritis (11).
DUOX2 requires a maturation factor, DUOX activator 2
(DUOXA2), to exit from the endoplasmic reticulum (ER) and
reach the apical plasma membrane (9). DUOX2 and
DUOXA2 proteins form a stable complex at the cell surface
that is fundamental for the enzymatic activity (15).
The heterodimerization of DUOX2 and DUOXA2 is a
prerequisite for reactive oxygen species production, but the
nature of their interaction is not known (12). The N-terminal
peroxidase-like ectodomain of the DUOX proteins differen-
tiates them from other NOX proteins. In previous studies, we
showed that mutations of cysteine residues in the N-terminal
domain of the human DUOX2 protein affect both targeting
and extracellular H2O2 production by human DUOX2, indi-
cating that these residues are critical for proper maturation of
the flavoprotein (7, 14). Disulfide (S-S) bonds, which are
promoted and maintained by the oxidizing environment of the
ER, play an important role in protein folding, stability, func-
tion, and protein–protein interaction (6). Incidentally, un-
paired cysteine thiols have been shown to cause ER retention.
In this study, we report the characterization of an in-
tramolecular disulfide bond between the N-terminal domain
and the second predicted extracellular loop of DUOX2, which
has an important structural implication in both export and
activity of DUOX2 by promoting covalent interaction be-
tween DUOX2 and its partner, DUOXA2. In addition, this
interaction is critical for DUOXA2 stability. Therefore, this
study contributes to a change of paradigm regarding the nature
of the relationship between the two proteins: DUOX2 displays
a chaperone-like function with respect to its functional partner.
Results
Covalent binding between DUOX2 and DUOXA2
The function of the long extracellular N-terminal domain
of DUOX2 remains unclear. Among the possible roles of this
domain, it has been proposed that it could play a key role in
the interaction with its maturation factor, DUOXA2. The N-
terminal region of DUOX2 contains five cysteines (Fig. 1A).
These residues might be involved in intra- and intermolecular
disulfide bonds that affect the global conformation of the
protein. To analyze the role of these cysteine residues in the
interaction with DUOXA2, we used the DUOX2 mutants
previously constructed where cysteines, 124, 351, 370, 568,
or 582, were, respectively, replaced by glycine (7). In addi-
tion to that previously observed with whole cells, H2O2
generation of particulate fractions from mutants C124G,
C568G, and C582G DUOX2-transfected cells was com-
pletely abolished, whereas the activities of mutants C351G
and C370G were only partially decreased (Fig. 1B). This
indicated that mutations of cysteine residues affecting
membrane translocation abolished both extra- and intracel-
lular activities.
The apparent molecular mass of DUOX2 protein after
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) varies depending on the redox environment
(10). In reducing conditions, the wild-type (WT) DUOX2
protein coexpressed with DUOXA2 was detected as two
bands very close in size, around 185 kDa (3). In nonreducing
conditions, the mobility of the WT DUOX2 decreased, and
DUOX2 was detected at around 250 kDa. This shift in the
electrophoretic mobility from 185 to 250 kDa, which corre-
sponds to the oxidized form of DUOX2 previously described
(10), could be explained by the presence of an intramolecular
disulfide bond. When such a bond is present, the protein may
not fully denature, altering its mobility. This mobility shift is
incompatible with DUOX2 dimerization. Importantly, as
shown in Figure 1B, only mutation of cysteine 124 totally
suppressed the mobility shift of DUOX2, indicating that
among the cysteine residues present in the ectodomain, only
this cysteine was implied in disulfide bond formation. This
bond is not artifactually generated during or after homoge-
nization since all experiments were performed in the pres-
ence of 20 mM N-ethylmaleimide (NEM) that prevents any
aberrant disulfide bond formation. Immunoblot analysis also
revealed that mutation of cysteines, 124, 568, and 582, which
suppressed DUOX2 activity, significantly affected the level
of expression of the maturation factor, DUOXA2. This
finding underlined that a correct structural conformation of
DUOX2 is essential for the stability of DUOXA2. This was
confirmed by using an HEK293 cell line stably expressing
DUOXA2 where transfection of WT DUOX2 compared with
the mutant DUOX2 C124G highly enhanced the level of
expression of DUOXA2 in these cells (Fig. 1C). Therefore,
these results show that DUOXA2 functions at a late stage of
maturation occurring after oxidative folding of DUOX2.
To investigate whether the DUOXA2 protein is degraded
via the proteasome-dependent pathway, we examined the
expression of DUOXA2 in HEK-293 cells coexpressing
mutant DUOX2 C124G after treatment with a proteasome
inhibitor, MG132 (Fig. 1D). Treatment of cells with MG132
remarkably enhanced the expression of DUOXA2 in a dose-
dependent manner. This had no effect on the H2O2-generating
activity, indicating that the absence of activity in these con-
ditions was mainly due to a misfolding of the DUOX2 N-
terminal region itself rather than to a decrease of DUOXA2
expression (Fig. 1E). The same results were obtained with
mutant cysteine 582 (Supplementary Fig. S1A; Supplemen-
tary Data are available online at www.liebertpub.com/ars).
We next assessed the targeting of both DUOXA2 and mutant
DUOX2 C124G protein to the plasma membrane in the
presence or in the absence of MG132 by flow cytometry and
immunofluorescence microcopy. N-terminal myc epitope-
tagged DUOXA2 was coexpressed in HEK293 cells with
either N-terminal hemagglutinin (HA) epitope-tagged
DUOX2 or HA-tagged DUOX2 C124G (Fig. 2A). While WT
DUOX2 was well expressed at the cell plasma membrane, no
surface signal was obtained for the mutant. This was asso-
ciated with a total absence of the maturation factor,
DUOXA2, at the cell surface. Analysis of cells by confocal
microscopy confirmed the retention of DUOXA2 at the ER
level when it was coexpressed with the mutant DUOX2 (Fig.
2B). Thus, these findings highlighted that the oxidized form
of DUOX2 is essential for both stability and trafficking of
DUOXA2 to the cell surface. Immunochemistry analysis of
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normal human thyroid tissue confirmed that DUOX2 and its
maturation factor, DUOXA2, are both expressed at the apical
surface of the thyrocytes (Fig. 2C). The shift of DUOX2 in
nonreducing conditions was also observed by immunoblot
analysis of total lysate prepared from human thyrocytes.
How the interaction between DUOX2 and DUOXA2 af-
fects the stability of DUOXA2 is unknown. A recent study
performed on the purified N-terminal peroxidase-like ecto-
domain of the counterpart DUOX1 supports the existence
of cysteine-mediated disulfide bridges for intermolecular
protein–protein interactions (13). Indeed, it is conceivable
that an intermolecular disulfide bond between the two pro-
teins may promote the stabilization. To verify this hypothe-
sis, coimmunoprecipitation experiments were carried out.
FIG. 1. Effects of cysteine mutations of ectodomain of DUOX2 on H2O2 production and on stability of both DUOX2
and DUOXA2 proteins. (A) Schematic representation of DUOX2 with the proposed topology in the membrane. The circles
indicate the relative positions of mutated cysteine residues. (B) NADPH-dependent H2O2 formation activity in the par-
ticulate fraction from HEK-293 cells transiently cotransfected with human DUOX2 or human DUOX2 mutant with human
DUOXA2 and from control HEK293 cells ( pcDNA3). Particulate fractions were incubated as described under the Materials
and Methods section. The error bars show the SE of three independent experiments. The Western blot compares the
electrophoretic properties of DUOX2 wild-type (WT) and mutant construct proteins under reducing and nonreducing
conditions. The reduced and oxidized forms are indicated by arrows. The expression of DUOXA2 was analyzed in the same
samples. (C) Cells stably transfected with human DUOXA2 were transiently transfected with DUOX2 WT or mutant
DUOX2 C124G. Proteins were analyzed by Western blot. (D) Cells stably transfected with human DUOXA2 were tran-
siently transfected with mutant DUOX2 C124G and treated with vehicle (DMSO) or with different concentrations of
MG132 for 12 h. After treatment, DUOX2 and DUOXA2 proteins were analyzed by Western blot. DUOX2 WT was taken
as the control. The level of vinculin protein was used as an internal control. (E) MG132 treatment does not restore the H2O2-
generating activity of human DUOXA2-HEK293 cells transiently transfected with mutant DUOX2 C124G. DUOX2, dual
oxidase 2; DUOXA2, DUOX activator 2.
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WT DUOX2 was coexpressed in HEK293 cells with
DUOXA2. Mutant DUOX2 C124G was taken as a control.
To prevent proteasome-mediated DUOXA2 degradation,
cells were treated with MG132 during the experiments. Cell
lysates, prepared in nonreducing conditions, were then sub-
jected to a proteomic analysis after immunoprecipitation with
anti-DUOX2 antibody. Proteins were prefractionated by SDS-
PAGE in nonreducing conditions (Fig. 3A). Proteomic analysis
of bands with an apparent molecular mass superior to 150 kDa
revealed that DUOXA2 only interacts with WT DUOX2
(Supplementary Fig. S1B). To check the interaction between
DUOX2 and DUOXA2, C-terminal myc epitope-tagged
DUOXA2 was coexpressed in HEK-293 cells with either WT
DUOX2 or mutant DUOX2 C124G, and total proteins were
analyzed under nonreducing conditions (Fig. 3B). Importantly,
the c-Myc antibody immunodetected a band with an apparent
molecular mass around 250 kDa where only WT DUOX2 was
detected, indicating the existence of a disulfide bridge between
DUOX2 and DUOXA2. To identify cysteine residues involved
in the interaction between DUOX2 and DUOXA2, we per-
formed immunoprecipitation experiments. C-terminal myc
epitope-tagged DUOXA2 was coexpressed in HEK293 cells
with each of the DUOX2 cysteine mutants. In the presence of
MG132, DUOXA2 and each of all DUOX2 mutants were
correctly expressed in cells, as shown in the analysis of input
preparations (Fig. 3C). DUOXA2 coimmunoprecipitated with
WT DUOX2 and mutants, DUOX2 C351G and C370G, found
to be active at the cell surface. In contrast, there was no in-
teraction with the other mutants of DUOX2, which are func-
tionally inactive. Taken together, these data demonstrate for
the first time that DUOXA2 interacts covalently with DUOX2
via disulfide bonds involving both cysteine residues 568 and
582 of DUOX2.
The acquisition of an intramolecular disulfide bond involving
the cysteine 124 appeared to be the rate-limiting step in DUOX2
maturation. Therefore, we looked for cysteine residues present
FIG. 2. Defective plasma
membrane targeting of
mutant HA-DUOX2 C124G
coexpressed with myc-
DUOXA2. (A) Representa-
tive histograms of flow
immunocytofluorometry ex-
periments. The upper panel
shows that MG132 (2 lM)
does not change the absence
of expression of mutant HA-
DUOX2 C124G at the cell
surface. The middle panel
shows that mutant HA-DUOX2
affects the cell surface targeting
of myc-DUOXA2 in the pres-
ence or in the absence of
MG132. The bottom panel
shows that intracellular expres-
sion of myc-DUOXA2 in cells
permeabilized with saponin is
decreased in the presence of
mutant HA-DUOX2, but
MG132 rescues the inhibition.
***P<0.001. (B) Surface ex-
pression of WT or mutant
HA-DUOX2 C124G in per-
meabilized HEK293 cells
cotransfected with myc-
DUOXA2. Magnification·63.
The nuclei were stained with-
DAPI. Note that mutant
DUOX2 and its partner are
condensed in a perinuclear
zone (C) Localization of
DUOX2 and DUOXA2 pro-
teins at the apical surface of
human thyrocytes analyzed by
immunohistochemistry. Hu-
man thyrocytes were analyzed
for DUOX2 expression under
reducing and nonreducing
conditions. HA, hemagglutinin.
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in predicted extracellular loops of DUOX2 that could form a
disulfide bridge with this cysteine residue located near the N-
terminal extreme part of the ectodomain (Fig. 1A). Because
cysteine residue 1162 appeared to be the only candidate, we
evaluated, at first, the effect of its mutation on the H2O2-
generating activity. This mutation not only suppressed the en-
zymatic activity but also the shift in the electrophoretic mobility
of DUOX2 detected in nonreducing conditions, confirming that
this cysteine is also involved in the oxidative folding of DUOX2
and forms an intramolecular disulfide bridge with cysteine 124.
Consequently, mutation of cysteine 1162 also affected the sta-
bility of DUOXA2 (Fig. 4A) and the targeting at the plasma
membrane of both DUOX2 and DUOXA2 (Fig. 4B). Im-
portantly, immunoprecipitation experiments showed that mu-
tation of cysteine 1162 prevented the covalent interaction
between DUOX2 and its maturation factor (Fig. 4C).
How DUOXA2 interacts with DUOX2?
Analysis of the human DUOXA1/2 sequence alignment
shows that there are two conserved cysteines, cysteine 167 and
cysteine 233, located within two different predicted extracel-
lular domains that may form intermolecular disulfide bond(s)
with DUOX2 (Fig. 5A). To explore the role of these cysteine
residues, they were individually mutated to glycines. WT
DUOX2 was coexpressed in HEK293 cells with either WT or
each mutant, C167G and C233G, of DUOXA2. Treatment of
cells with MG132 inhibited the degradation of either DUOXA2
mutant, indicating that C169G and C233G mutations generated
unstable proteins (Supplementary Fig. S1C). These mutations
affected the H2O2-generating activities by 50%, and treatment
of cells with MG132 did not restore the activity (Fig. 5B).
These data indicated that these cysteines are important for the
function of the complex DUOX2/DUOXA2 and could be in-
volved in a disulfide bridge with DUOX2. Analysis of protein
expressions by Western blot in nonreducing conditions (Fig.
5C) and immunoprecipitation experiments (Fig. 5D) demon-
strated that the cysteines, 167 and 233, of DUOXA2 are both
involved in an intermolecular disulfide bridge with DUOX2.
Discussion
In the present study, we have identified an intramolecular
disulfide bridge between cys-124 and cys-1162 that is
FIG. 3. DUOXA2 interacts
covalently with DUOX2. (A)
Immunoprecipitated DUOX2
and mutant DUOX2 C124G
were analyzed by SDS-PAGE
in nonreducing conditions.
Proteins were stained as de-
scribed under the Materials
and Methods section. Bands
with a molecular weight su-
perior to 150 kDa were excised
from the gel and micro-
sequenced. (B) Covalent in-
teraction between DUOX2 and
DUOXA2 was analyzed by
Western blot analysis in non-
reducing conditions. DUOX2
or mutant DUOX2 C124G
was coexpressed with myc-
DUOXA2 in HEK293 cells.
The expression of DUOX2
was detected by using anti-
hDUOX2 and DUOXA2 was
detected by using anti-myc.
(C) Cells were cotransfected
with DUOX2 or mutant
DUOX2 and myc-DUOXA2.
Anti-myc immunoprecipitates
(IP: c-Myc) of the cell lysates
were separated by SDS-PAGE
in reducing conditions and
analyzed by Western blotting
for DUOX2 and myc-
DUOXA2. Analysis of the cell
lysates used as the input in
immunoprecipitation is shown
in the upper three panels.
SDS-PAGE, sodium dodecyl
sulfate–polyacrylamide gel
electrophoresis.
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essential for the structure and the function of DUOX2. These
two cysteine residues reside, respectively, in the N-terminal
ectodomain and in an extracellular loop connecting TMs 4
and 5 of the DUOX. Therefore, these cysteines, which are
distant in the linear sequence, appear to be in close proximity
in the native protein. At first sight, this was unexpected be-
cause, most of the time, intramolecular disulfide bonds form
between adjacent cysteines located in the same loop. Thus, in
this context, it was rather considered initially that cys-124
forms, in the first place, a disulfide bridge with one of the four
other cysteine residues located in the N-terminal ectodomain
since they enter the ER lumen first. Once again, this finding
highlights the complexity of the process related to the protein
folding in the ER.
The existence of this intramolecular bridge, which appears
to have some functional significance, has been evidenced by a
shift in the electrophoretic mobility for the WT DUOX2
under nonreducing conditions that is eliminated by mutation
of either cysteine 124 or cysteine 1162. Of importance, this
shift is not restricted to the recombinant expression system
used for this study. It was also observed in human primary
thyrocytes where DUOX2 is well expressed, indicating that
the oxidative folding of DUOX2 takes place in physiolog-
ical conditions. We cannot exclude that other cysteines in
the DUOX2 can form intramolecular disulfide bonds, but
our results demonstrate the importance of both cysteine 124
and cysteine 1162 in a conformation-dependent mobility
shift.
The structure of the N-terminal ectodomain of DUOX2 by
itself promotes the formation of the intramolecular bridge
between the cysteine residues, 124 and 1162. Thus, any
mutation in the N-terminal domain that modifies its own
conformation may prevent the formation of this in-
tramolecular disulfide bond. This was probably the case for
two natural DUOX2 mutants (Q36H and R376W) implicated
in congenital hypothyroidism for which the absence of
FIG. 4. Cysteine 1162 is
involved in the intramole-
cular disulfide bond essential
for the activity and the tar-
geting of DUOX2. (A) HA-
DUOX2 (WT) and mutant HA-
DUOX2 C1162G proteins
were transiently expressed with
DUOXA2 protein in HEK293
cells. The extracellular H2O2-
generating activity was mea-
sured after 48 h. The expression
of the WT and mutant DUOX2
was analyzed by immunoblot-
ting in nonreducing and reduc-
ing conditions. DUOXA2
expression was assessed by
using anti-DUOXA2 antibody.
***P<0.001. (B) Represen-
tative histograms of flow im-
munocytofluorometry experi-
ments. Absence of cell surface
expression of the mutant HA-
DUOX2 C1162G was associ-
ated with an absence of cell
surface expression of N-termi-
nal cMyc epitope-tagged hu-
man DUOXA2. **P<0.01.
(C) Cells were cotransfected
with HA-DUOX2 or mutant
HA-DUOX2 C1162G in the
presence of myc-DUOXA2.
Anti-myc immunoprecipitates
of the cell lysates were sepa-
rated by SDS-PAGE and ana-
lyzed by Western blotting.
Analysis of the cell lysates used
as the input in immunoprecipi-
tation is shown in the upper two
panels.
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trafficking and activity was related to the absence of the
oxidized form (10).
In general, intramolecular disulfide bridge formation is
critically important for the stability of the neosynthesized
protein and determines its own fate, that is, degradation or
targeting to the plasma membrane. Importantly, the oxidative
folding of DUOX2 was found to also determine the fate of its
maturation factor, DUOXA2. Suppression of the intra-
molecular disulfide bond in DUOX2 induced preferentially a
degradation of DUOXA2, highlighting that the oxidized form
of DUOX2 influences the stability of its own partner. How-
ever, the inhibition of proteasomal protein degradation of
FIG. 5. Cysteines, 167 and 233, of DUOXA2 form disulfide bonds with DUOX2. (A) Schematic representation of
DUOXA2 with the proposed topology in the membrane. The circles indicate the relative positions of mutated cysteine residues.
(B) C-terminal cMyc epitope-tagged DUOXA2 (WT) and C-terminal cMyc epitope-tagged mutant DUOXA2 C167G or C233G
proteins were transiently expressed with WT DUOX2 protein in HEK293 cells treated with increasing concentrations of
MG132. **P< 0.01, ***P< 0.001. (C) Expression of DUOX2 and DUOXA2 proteins analyzed by immunoblotting in nonre-
ducing conditions by using, respectively, anti-DUOX2 and anti-myc antibodies. (D)Cells were cotransfected with HA-DUOX2 in
the presence of WT DUOXA2-myc or mutant DUOXA2-myc. Anti-HA immunoprecipitates of the cell lysates were separated by
SDS-PAGE in reducing conditions and analyzed by Western blotting by using anti-DUOX2 and anti-myc, respectively. Analysis
of the cell lysates used as input in immunoprecipitation is shown in the upper two panels. (E) Schematic representation of the
DUOX2/DUOXA2 complex in the cell membrane. The intramolecular bond between DUOX2 cysteine residues 124 and 1162 is
indicated. The intermolecular bonds between DUOX2 and DUOXA2 involved, respectively, N-terminal cysteine residues 568
and 582 of DUOX2 and cysteine residues 167 and 233 of DUOXA2. Several combinations are considered.
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DUOXA2 by MG132 was not sufficient to restore the targeting
to the plasma membrane and therefore the H2O2-generating
activity of the DUOX. The function of DUOXA2 was also
altered, indicating that it is totally dependent on a well-defined
conformation of the N-terminal ectodomain of DUOX2. Re-
cently, except for cysteine 124, the four cysteine residues
(Cys351, cys370, Cys568, and Cys582) were mapped onto a
structural model of an isolated DUOX2 N-terminal region
(13). Each cysteine residue was found to exist as a solvent-
exposed residue situated on one face of the protein surface,
suggesting that it may enable protein–protein interaction that is
required for maturation. Mutations of two of these cysteines, that
is, cys-568 and cys-582, that did not prevent the oxidative
folding of DUOX2, were found to impair both stability and
function of DUOXA2 (Fig. 1B). Our findings show that these
two cysteines are involved in covalent interactions through
disulfide bridges with cysteines, 167 and 233, located in two
different extracellular loops of the maturation factor, DUOXA2.
These intermolecular disulfide bonds, important for the stability
of DUOXA2, play therefore a critical role in both targeting and
functioning of the DUOX at the plasma membrane.
In conclusion, we have identified an intramolecular dis-
ulfide bridge that is essential for the structure and the function
of DUOX2. This disulfide bridge formed in the ER appears to
be a key event in the trafficking of the DUOX2/DUOXA2
complex as it promotes an appropriate conformation of the
N-terminal region, which is propitious to subsequent cova-
lent interactions through disulfide bridges with the matura-
tion factor, DUOXA2 (Fig. 5E). We highlighted that both
stability and function of DUOXA2 are totally dependent on
the oxidative folding of DUOX2. These findings change the
paradigm concerning the nature of the relationship between
the two proteins and provide us with opportunities to design
potential therapeutics targeting this DUOX2-DUOXA2 in-
teraction to control the DUOX2-dependent H2O2-generating
activity that could be deleterious in pathological conditions.
Materials and Methods
Cell culture, mutagenesis, and transfection
HEK293 cells were cultured in DMEM (high glucose;
PAA) supplemented with 10% (v/v) fetal calf serum and
penicillin/streptomycin (100 lg/ml; Life Technologies Ltd).
Primary human thyroid cells were cultured as previously
described (19). Normal, human thyroid tissue specimens
were collected at Institut Gustave Roussy in accordance with
local and national ethics laws. Informed consent was ob-
tained from all patients.
The mutagenesis of cysteine residues has been previously
performed by using the QuikChange site-directed mutagen-
esis kit (Stratagene) and a pcDNA3 plasmid containing the
full-length human (h) WT DUOX2 (hDUOX2-pcDNA3) as
a template (7). The NH2-terminal hemagglutinin epitope-
tagged human DUOX2 (HA-DUOX2-pcDNA3), kindly gi-
ven by Dr. Xavier de Deken (Brussels, Belgium), and the
NH2-terminal cMyc epitope-tagged human DUOXA2 as the
COOH-terminal cMyc epitope-tagged human DUOXA2
(cMyc-DUOXA2-pcDNA3) were described elsewhere (9).
In transient cell transfection experiments, HEK293 cells
reaching 50%–70% confluence were transfected in 24-well
plates using X-tremeGENE HP DNA Transfection Reagent
with the protocol recommended by the manufacturer (Roche).
At 24 h after transfection, the medium was changed and 20lM
hemin was added, and the transfected cells were treated with
the test agents for the times and at the concentrations indicated
in each experiment. After 48 h, the cells were harvested.
Measurement of H2O2 generation
H2O2 generation was quantified by the Amplex red/horse-
radish peroxidase assay (Sigma Aldrich), which detects the
accumulation of a fluorescent oxidized product. Cells
(2· 104) in Dulbecco’s phosphate-buffered saline (D-PBS)
with CaCl2 and MgCl2 were incubated with D-glucose (1 mg/
ml), ionomycin (1lM; Sigma Aldrich), SOD (100 U/ml;
Sigma Aldrich), horseradish peroxidase (0.5 U/ml; Roche),
and Amplex red (50lM; Sigma Aldrich), and immediately the
fluorescence was measured in a microplate reader (Victor3;
PerkinElmer) at 37C for 30 min using excitation at 530 nm
and emission at 595 nm. Particulate fractions (75lg) were
incubated in 50 mM sodium phosphate buffer (pH 7.2) con-
taining sucrose (150 mM), EGTA (1 mM), CaCl2 (1.5 mM),
SOD (200 U/ml), horseradish peroxidase (0.5 U/ml), and
Amplex red (50lM). The reaction was started by adding
0.1 mM NADPH and the fluorescence was measured as de-
scribed above. H2O2 release was quantified (nanomoles H2O2
per hour per 105 cells) using standard calibration curves.
Preparation of the cellular particulate fraction
Cells were washed with PBS and scraped into the same
solution supplemented with a mixture of protease inhibitors
(5lg/ml aprotinin, 5lg/ml leupeptin, 1 lg/ml pepstatin,
157lg/ml benzamidine). After centrifuging at 200 g for
10 min at 4C, the cell pellet was homogenized using a mo-
tor-driven Teflon pestle homogenizer in 2 ml of 50 mM so-
dium phosphate buffer containing 0.25 M sucrose, 0.1 mM
dithiothreitol, 1 mM EGTA (pH 7.2), and the mixture of
protease inhibitors. After centrifuging at 200,000 g for
30 min, the pellet was resuspended in 0.5 ml of 50 mM so-
dium phosphate buffer (pH 7.2) containing 0.25 M sucrose,
1 mM MgCl2, and the mixture of protease inhibitors.
Western blot analysis
Cell extracts were prepared as previously described (19) by
adding 20 mM NEM in lysis buffer. Samples were then son-
icated for 15 s. Protein samples (10–30lg) supplemented with
or without 2.5% (v/v) ß-mercaptoethanol and 10% glycerol
were denatured for 2 min at 100C, subjected to SDS-PAGE
using a 4%–12% or 8%–16% tris-glycine polyacrylamide
minigel (Life Technologies Ltd), and electrotransferred to
0.2-lm Protran BA83 nitrocellulose sheets (Schleicher &
Schuell). The immunodetection of DUOX2 was done as pre-
viously described (14). Anti-DUOXA2 has been previously
described (20). Immunodetection was also done by using pri-
mary antibodies: anti-vinculin (Abcam), anti-HA (clone 3F10;
Roche), and anti-cMyc (Santa Cruz Biotechnology).
Immunoprecipitation
After preparation of particulate fractions, protein pellets
were incubated overnight with Nonidet P40 at 4C in nonre-
ducing conditions. After centrifugation, soluble proteins were
immunoprecipitated (IP) with Myc or HA antibody as re-
commended by the kit manufacturer (Sigma Aldrich).
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Proteomic study
HEK293 cells were transiently cotransfected with WT
DUOX2 or mutant DUOX2 in the presence of DUOXA2.
Twelve hours before harvesting, the cells were treated with
1 lM of MG132. The cells from two Petri dishes (about
2 · 107 cells) were then lysed in 0.5 ml 10 mM Tris/HCl
buffer, pH 7.5, containing 150 mM NaCl, 0.5% Nonidet P40,
2 mM EDTA, 20 mM NEM, and a cocktail of protease in-
hibitors (SIGMA). The lysate was incubated overnight at
4C and centrifuged at 200,000 g for 30 min. The superna-
tant was used for immunoprecipitation experiments.
DUOX2 and mutant DUOX2 were IP in nonreducing con-
ditions by using the Dynabeads Protein A immunoprecipi-
tation kit (Invitrogen) with an antibody raised against the
first intracellular domain Glu636-Arg1039 of human DUOX2
(anti-hDUOX2). The Ab-Ag complex was eluted with the
nonreducing SDS-PAGE sample buffer before being sub-
jected to migration using a 4%–12% linear gradient poly-
acrylamide slab minigel (Invitrogen). Proteins were stained
by using the colloidal blue staining kit (Invitrogen), and
bands were excised from gels.
In gel digestion
The gel bands were washed first with 100ll of ammonium
bicarbonate 25 mM (SIGMA 11204)/acetonitrile (SIGMA
34967) 50/50 v/v by mixing for 10 min at room temperature
(RT), then with 100 ll of 100% acetonitrile by mixing for
10 min at RT. These two steps were repeated once in the same
order. Samples were dried on a speed vac for 2 min. Twenty
microliters of trypsin (Calbiochem 650279) at 11.55 ng/ll
was added to each gel piece. After incubation at RT for
15 min, 20ll of ammonium bicarbonate 50 mM was added.
Samples were incubated at 37C overnight. Supernatants
were separated from gel pieces and transferred to analysis
vials. Twenty microliters of formic acid 5% (SIGMA 33015-
1l)/acetonitrile 30/70 v/v was added to each piece of gel to
extract remaining peptides. Supernatants were combined to-
gether and then dried on the speed vac. Ten microliters of
97% water, 3% acetonitrile, and 0.1% formic acid was added
to solubilize the tryptic peptides.
Analysis on nanoHPLC-chip cube ion trap (Agilent)
The tryptic peptide mixtures were analyzed with na-
noHPLC (Agilent Technologies 1200) directly coupled to an
ion trap mass spectrometer (BRUKER 6300 series) equipped
with a nanoelectrospray source. Three microliters of the
peptide mixture was separated on ProtID-Chip-43 II 300A
C18 43 mm col (G4240-62005 Agilent) with a 30 min-gra-
dient from 3% to 97% of acetonitrile.
The acquisition was performed as following: one full-scan
MS over the range of 200–2200 m/z, followed by three data-
dependent MS/MS scans on the three most abundant ions in
the full scan. The data were analyzed on the Spectrum Mill
MS Proteomics Workbench Rev A.03.03.084 SR4 with
the following settings: DATA EXTRACTOR: MH+ 200–
4400 Da; Scan range 0–30 min.
MS/MS SEARCH: Swiss-Prot database; Homo sapiens;
trypsin; two missed cleavages; oxidized methionine (M),
phosphorylated S, T, Y: masses are monoisotopic; and precur-
sor mass tolerance–2 Da and product mass tolerance–0.8 Da.
Flow immunocytofluorometry
For surface protein staining, cells were detached from the
plates with PBS containing 5 mM EDTA/EGTA and incubated
for 30 min at RT with a rat anti-HA of high affinity (clone
3F10; Roche) or with a mouse monoclonal anti-Myc (Santa
Cruz Biotechnology), respectively, for NH2-terminal HA
epitope-tagged human DUOX2 and NH2-terminal cMyc epi-
tope-tagged human DUOXA2 surface immunofluorescence
staining. The samples were washed once with D-PBS/0.1%
bovine serum albumin (BSA) and incubated for 30 min with
Alexa 488-conjugated antirat IgG or Alexa 568-conjugated
antimouse IgG diluted in D-PBS/0.1% BSA (Life Technolo-
gies Ltd). After two washing steps, the cells were resuspended
in D-PBS/0.1% BSA. For detection of intracellular HA-
DUOX2 or DUOXA2-myc, detached cells were fixed in 1%
paraformaldehyde/D-PBS for 10 min at 4C, washed in
D-PBS, and permeabilized for 20 min with 0.2% saponin in
D-PBS/0.1% BSA. Binding of antibodies was done as above.
Fluorescence was assayed using a BD Accuri C6 Flow
Cytometer (BD Biosciences), counting 10,000 events per
sample. Relative protein expression was determined by cal-
culating differences in total fluorescence between the sample
and an equal-sized population of pcDNA3-DUOX2 and
pcDNA3-DUOXA2-transfected cells corresponding to 100%.
Immunofluorescence studies
Transfected cells grown on glass coverslips were washed in
D-PBS and fixed in 4% paraformaldehyde/D-PBS for 10 min.
Nonspecific binding sites were blocked with 3% BSA/D-PBS
for 30 min. For staining of NH2-terminal HA epitope-tagged
human DUOX2 or NH2-terminal cMyc epitope-tagged human
DUOXA2, cells were incubated for 2 h with rat anti-HA clone
3F10 or with mouse anti-Myc in TBS buffer containing 0.3%
BSA. After three washing steps in TBS with 0.1% Tween,
Alexa 488-conjugated anti-rat IgG or Alexa 568-conjugated
anti-mouse IgG diluted in TBS/0.3% BSA (Life Technologies
Ltd) was used as the secondary antibody. After two washing
steps in TBS 0.1% Tween and staining with Hoechst 33342
fluorochrome (Life Technologies Ltd), the slides were moun-
ted with Dako Fluorescence Mounting Medium (Dako Den-
mark). Fluorescent images were captured on a confocal
microscope (Leica DM IRE 2; Perkin Elmer).
Statistical analysis
Data are represented as the means – standard deviations
of the results of at least three independent experiments.
Student’s t-test was used to calculate significance values.
Significant values are indicated as (*) p-value of < 0.05 or
(**) p-value of < 0.01 or (***) p-value of < 0.001.
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DUOX¼ dual oxidase
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